$BIOLQ
BIOLASE, INC

2017 Form 10-K Financial Statement

#000156459018005648 Filed on March 14, 2018

View on sec.gov

Income Statement

Concept 2017 2016 Q4 2015 Q4
Revenue $46.93M $13.76M $14.52M
YoY Change 39333.61% -5.23% 9.67%
Cost Of Revenue $31.80M $8.360M $8.990M
YoY Change 0.95% -7.01% 9.23%
Gross Profit $15.13M $5.400M $5.530M
YoY Change -25.52% -2.35% 10.38%
Gross Profit Margin 32.23% 39.24% 38.09%
Selling, General & Admin $26.43M $7.220M $6.050M
YoY Change -3.79% 19.34% -19.12%
% of Gross Profit 174.73% 133.7% 109.4%
Research & Development $6.229M $2.300M $1.750M
YoY Change -20.14% 31.43% 29.63%
% of Gross Profit 41.18% 42.59% 31.65%
Depreciation & Amortization $1.203M $270.0K $290.0K
YoY Change 14.79% -6.9% 70.59%
% of Gross Profit 7.95% 5.0% 5.24%
Operating Expenses $33.16M $9.520M $7.800M
YoY Change -5.97% 22.05% -11.66%
Operating Profit -$18.04M -$4.120M -$2.270M
YoY Change 20.57% 81.5% -40.58%
Interest Expense $42.00K -$280.0K -$130.0K
YoY Change -116.15% 115.38% -50.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$17.43M -$4.390M -$2.410M
YoY Change 14.54% 82.16% -40.79%
Income Tax -$21.68M $30.00K $50.00K
% Of Pretax Income
Net Earnings -$16.85M -$4.430M -$2.460M
YoY Change 9.63% 80.08% -40.15%
Net Earnings / Revenue -35.91% -32.19% -16.94%
Basic Earnings Per Share -$0.28
Diluted Earnings Per Share -$0.28 -$327.7K -$211.2K
COMMON SHARES
Basic Shares Outstanding 73.76M 67.57M
Diluted Shares Outstanding 73.76M

Balance Sheet

Concept 2017 2016 Q4 2015 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.65M $8.920M $11.70M
YoY Change 30.61% -23.76% -62.93%
Cash & Equivalents $11.65M $9.175M $11.70M
Short-Term Investments
Other Short-Term Assets $1.980M $1.760M $1.590M
YoY Change 12.5% 10.69% -8.09%
Inventory $12.30M $13.52M $12.57M
Prepaid Expenses
Receivables $10.05M $9.784M $8.948M
Other Receivables $70.00K $23.00K $37.00K
Total Short-Term Assets $36.05M $33.99M $34.80M
YoY Change 6.06% -2.34% -36.49%
LONG-TERM ASSETS
Property, Plant & Equipment $3.670M $4.478M $3.727M
YoY Change -18.08% 20.15% 187.8%
Goodwill $2.926M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $330.0K $550.0K $747.0K
YoY Change -40.0% -26.37% 176.67%
Total Long-Term Assets $6.930M $7.953M $7.451M
YoY Change -12.83% 6.74% 61.8%
TOTAL ASSETS
Total Short-Term Assets $36.05M $33.99M $34.80M
Total Long-Term Assets $6.930M $7.953M $7.451M
Total Assets $42.98M $41.94M $42.25M
YoY Change 2.48% -0.74% -28.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.110M $9.130M $5.960M
YoY Change -44.03% 53.19% -28.71%
Accrued Expenses $4.690M $4.770M $4.800M
YoY Change -1.68% -0.63% -1.44%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $160.0K $170.0K
YoY Change -100.0% -5.88%
Total Short-Term Liabilities $13.37M $18.01M $15.11M
YoY Change -25.76% 19.19% -6.44%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $160.0K
YoY Change -100.0%
Other Long-Term Liabilities $250.0K $268.0K $338.0K
YoY Change -76.42% -20.71% -35.0%
Total Long-Term Liabilities $250.0K $268.0K $338.0K
YoY Change -76.42% -20.71% -35.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.37M $18.01M $15.11M
Total Long-Term Liabilities $250.0K $268.0K $338.0K
Total Liabilities $13.72M $19.88M $17.33M
YoY Change -30.99% 14.72% -0.14%
SHAREHOLDERS EQUITY
Retained Earnings -$178.3M -$163.0M
YoY Change 9.43%
Common Stock $201.3M $188.7M
YoY Change 6.67% 1.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $29.26M $22.07M $24.93M
YoY Change
Total Liabilities & Shareholders Equity $42.98M $41.94M $42.25M
YoY Change 2.48% -0.73% -28.87%

Cashflow Statement

Concept 2017 2016 Q4 2015 Q4
OPERATING ACTIVITIES
Net Income -$16.85M -$4.430M -$2.460M
YoY Change 9.63% 80.08% -40.15%
Depreciation, Depletion And Amortization $1.203M $270.0K $290.0K
YoY Change 14.79% -6.9% 70.59%
Cash From Operating Activities -$18.41M -$3.150M -$2.820M
YoY Change 73.76% 11.7% -52.45%
INVESTING ACTIVITIES
Capital Expenditures $747.0K -$350.0K -$550.0K
YoY Change -47.17% -36.36% 5400.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities -$747.0K -$350.0K -$550.0K
YoY Change -47.17% -36.36% 5400.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $21.76M
YoY Change 128.58%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 21.62M -50.00K -90.00K
YoY Change 131.21% -44.44% -100.26%
NET CHANGE
Cash From Operating Activities -18.41M -3.150M -2.820M
Cash From Investing Activities -747.0K -350.0K -550.0K
Cash From Financing Activities 21.62M -50.00K -90.00K
Net Change In Cash 2.721M -3.550M -3.460M
YoY Change -199.89% 2.6% -111.98%
FREE CASH FLOW
Cash From Operating Activities -$18.41M -$3.150M -$2.820M
Capital Expenditures $747.0K -$350.0K -$550.0K
Free Cash Flow -$19.16M -$2.800M -$2.270M
YoY Change 59.53% 23.35% -61.66%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
24925000
CY2017 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
42000
CY2017 us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
-505000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
11000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17433000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
42056000
CY2017 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
3978000
CY2016 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
2184000
CY2017 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20829000
CY2016 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17555000
CY2017 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
CY2017 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
CY2017 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73759000
CY2016 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
70000
CY2015 biol Litigation Expense Recovered
LitigationExpenseRecovered
731000
CY2016 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
51000
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
337000
CY2017 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
73759000
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
44000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3350000
CY2015 biol Common Stock Issuance Cost
CommonStockIssuanceCost
3000
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3065000
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2145000
CY2017 biol Stock Issued During Period Value Rights Offering Net
StockIssuedDuringPeriodValueRightsOfferingNet
11358000
CY2017 biol Convertible Preferred Stock And Warrants Issuance Cost
ConvertiblePreferredStockAndWarrantsIssuanceCost
251000
CY2015 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
880000
CY2015 us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
-6000
CY2015 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
86000
CY2015 us-gaap Inventory Write Down
InventoryWriteDown
647000
CY2015 biol Provision For Sales Returns Allowance
ProvisionForSalesReturnsAllowance
100000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
2207000
CY2017 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-419000
CY2017 us-gaap Increase Decrease In Customer Deposits
IncreaseDecreaseInCustomerDeposits
-74000
CY2017 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-5003000
CY2015 biol Increase Decrease In Accrued Legal Settlement
IncreaseDecreaseInAccruedLegalSettlement
1664000
CY2017 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-397000
CY2016Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
4837000
CY2017Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1162000
CY2016Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
2261000
CY2017Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
7183000
CY2016Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
6425000
CY2017Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
1900000
CY2016Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
1700000
CY2016Q4 biol Property Plant And Equipment Gross Excluding Land
PropertyPlantAndEquipmentGrossExcludingLand
10551000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7426000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6225000
CY2017Q4 biol Property Plant And Equipment Net Excluding Land
PropertyPlantAndEquipmentNetExcludingLand
3498000
CY2017Q4 us-gaap Land
Land
176000
CY2016Q4 us-gaap Land
Land
152000
CY2016Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
933000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-18412000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
747000
CY2015 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
25000
CY2017 us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
146000
CY2016 us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
171000
CY2017 biol Proceeds From Issuance Of Equity Net Of Issuance Costs
ProceedsFromIssuanceOfEquityNetOfIssuanceCosts
21761000
CY2016 biol Proceeds From Issuance Of Equity Net Of Issuance Costs
ProceedsFromIssuanceOfEquityNetOfIssuanceCosts
9520000
CY2015 biol Deposit On Capital Lease
DepositOnCapitalLease
42000
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3000
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1000
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
44000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
21618000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
9350000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-105000
CY2017 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
262000
CY2016 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-64000
CY2015 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-206000
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2721000
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2775000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-19861000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11699000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31560000
CY2017 us-gaap Interest Paid
InterestPaid
1000
CY2016 us-gaap Interest Paid
InterestPaid
4000
CY2015 us-gaap Interest Paid
InterestPaid
4000
CY2017 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
164000
CY2016 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
76000
CY2015 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
57000
CY2015 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
378000
CY2017 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
102000
CY2016 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
251000
CY2015 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1137000
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of these consolidated financial statements in conformity with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;) requires the Company to make estimates and assumptions that affect amounts reported in the consolidated financial statements and the accompanying notes. Significant estimates in these consolidated financial statements include allowances on accounts receivable, inventory, and deferred taxes, as well as estimates for accrued warranty expenses, goodwill and the ability of goodwill to be realized, revenue deferrals, effects of stock-based compensation and warrants, contingent liabilities, and the provision or benefit for income taxes. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may differ materially from those estimates. </p></div>
CY2017 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk, Interest Rate Risk and Foreign Currency Exchange Rate </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Financial instruments which potentially expose the Company to a concentration of credit risk consist principally of cash and cash equivalents, restricted cash, and trade accounts receivable. The Company maintains its cash and cash equivalents and restricted cash with established commercial banks. At times, balances may exceed federally insured limits. To minimize the risk associated with trade accounts receivable, management performs ongoing credit evaluations of customers&#8217; financial condition and maintains relationships with the Company&#8217;s customers that allow management to monitor current changes in business operations so the Company can respond as needed. The Company does not, generally, require customers to provide collateral before it sells them its products. However, the Company has required certain distributors to make prepayments for significant purchases of products. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Substantially all of the Company&#8217;s revenue is denominated in U.S.&#160;dollars, including sales to international distributors. Only a small portion of its revenue and expenses is denominated in foreign currencies, principally the Euro and Indian Rupee. The Company&#8217;s foreign currency expenditures primarily consist of the cost of maintaining offices, consulting services, and employee-related costs. During the years ended December 31, 2017, 2016, and 2015, the Company did not enter into any hedging contracts. Future fluctuations in the value of the U.S.&#160;dollar may affect the price competitiveness of the Company&#8217;s products outside the U.S.&nbsp;&nbsp;</p></div>
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.011
CY2017Q4 biol Proceeds From Issuance Of Equity Net Of Issuance Costs
ProceedsFromIssuanceOfEquityNetOfIssuanceCosts
11400000
CY2017Q2 biol Proceeds From Issuance Of Equity Net Of Issuance Costs
ProceedsFromIssuanceOfEquityNetOfIssuanceCosts
10200000
CY2016Q3 biol Proceeds From Issuance Of Equity Net Of Issuance Costs
ProceedsFromIssuanceOfEquityNetOfIssuanceCosts
9500000
CY2017Q4 biol Working Capital
WorkingCapital
22700000
CY2017Q4 biol Cash And Cash Equivalents And Restricted Cash
CashAndCashEquivalentsAndRestrictedCash
11900000
CY2017 us-gaap Depreciation
Depreciation
1203000
CY2016 us-gaap Depreciation
Depreciation
997000
CY2015 us-gaap Depreciation
Depreciation
817000
CY2017 us-gaap Number Of Reporting Units
NumberOfReportingUnits
1
CY2017Q4 biol Undelivered Elements Training Installation And Product And Support Services
UndeliveredElementsTrainingInstallationAndProductAndSupportServices
980000
CY2016Q4 biol Undelivered Elements Training Installation And Product And Support Services
UndeliveredElementsTrainingInstallationAndProductAndSupportServices
1404000
CY2017 us-gaap Sales Returns And Allowances Goods
SalesReturnsAndAllowancesGoods
210000
CY2016 us-gaap Sales Returns And Allowances Goods
SalesReturnsAndAllowancesGoods
210000
CY2017Q4 us-gaap Extended Product Warranty Accrual
ExtendedProductWarrantyAccrual
1600000
CY2016Q4 us-gaap Extended Product Warranty Accrual
ExtendedProductWarrantyAccrual
1500000
CY2017Q4 biol Percentage Of Fair Value Of Exchange To Recognize Revenue
PercentageOfFairValueOfExchangeToRecognizeRevenue
0.25
CY2016Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
1706000
CY2015Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
2188000
CY2017 us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
492000
CY2016 us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
348000
CY2015 us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
1715000
CY2017 us-gaap Product Warranty Expense
ProductWarrantyExpense
1008000
CY2016 us-gaap Product Warranty Expense
ProductWarrantyExpense
830000
CY2015 us-gaap Product Warranty Expense
ProductWarrantyExpense
976000
CY2017Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
1190000
CY2015Q4 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
843000
CY2017Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1120000
CY2015Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1345000
CY2017 us-gaap Advertising Expense
AdvertisingExpense
298000
CY2016 us-gaap Advertising Expense
AdvertisingExpense
351000
CY2015 us-gaap Advertising Expense
AdvertisingExpense
929000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2207000
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3065000
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3350000
CY2017Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
3400000
CY2016Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
4000000
CY2017 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y
CY2017 biol Medical Devices Excise Tax Effective Start Date
MedicalDevicesExciseTaxEffectiveStartDate
2018-01-01
CY2017 biol Medical Devices Excise Tax Suspension End Date
MedicalDevicesExciseTaxSuspensionEndDate
2020-01-01
CY2017Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
10047000
CY2016Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
9699000
CY2017Q4 biol Royalty Revenues Receivable
RoyaltyRevenuesReceivable
71000
CY2016Q4 biol Royalty Revenues Receivable
RoyaltyRevenuesReceivable
62000
CY2017Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
6000
CY2016Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
23000
CY2017Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
800000
CY2016Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
1200000
CY2017Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
3953000
CY2017Q4 biol Property Plant And Equipment Gross Excluding Land
PropertyPlantAndEquipmentGrossExcludingLand
10924000
CY2016Q4 biol Property Plant And Equipment Net Excluding Land
PropertyPlantAndEquipmentNetExcludingLand
4326000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2115000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2147000
CY2016Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
159000
CY2016Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
906000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
213000
CY2017Q4 us-gaap Extended Product Warranty Accrual Current
ExtendedProductWarrantyAccrualCurrent
1634000
CY2016Q4 us-gaap Extended Product Warranty Accrual Current
ExtendedProductWarrantyAccrualCurrent
1487000
CY2017Q4 biol Deferred Royalties Current
DeferredRoyaltiesCurrent
22000
CY2016Q4 biol Deferred Royalties Current
DeferredRoyaltiesCurrent
142000
CY2017Q4 us-gaap Deferred Revenue
DeferredRevenue
2636000
CY2016Q4 us-gaap Deferred Revenue
DeferredRevenue
3033000
CY2017Q4 biol Deferred Royalties Noncurrent
DeferredRoyaltiesNoncurrent
11000
CY2016Q4 biol Deferred Royalties Noncurrent
DeferredRoyaltiesNoncurrent
23000
us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
0
CY2017 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2016 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
51000
CY2015 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
63000
CY2016Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2800000
CY2016Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2800000
CY2017Q4 us-gaap Goodwill Gross
GoodwillGross
2926000
CY2017 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
19000
CY2016 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
22000
CY2015 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
30000
CY2017Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2800000
CY2017 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
112000
CY2016 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
91000
CY2015 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
117000
CY2017 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-694000
CY2016 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
60000
CY2015 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
61000
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2017Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2800000
CY2017 biol Indefinite Lived Intangible Assets Useful Life
IndefiniteLivedIntangibleAssetsUsefulLife
Indefinite life
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.034
CY2017 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
93000
CY2016 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
69000
CY2015 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
87000
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.906
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.404
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.402
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.032
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.030
CY2015 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.031
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.017
CY2016 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.034
CY2015 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.031
CY2016 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.002
CY2015 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.001
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.010
CY2016 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.006
CY2015 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.004
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-1.271
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.005
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.009
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.020
CY2016 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.002
CY2015 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.005
CY2015 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.009
CY2017Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
-21000
CY2016Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
47000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves
1130000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves
2117000
CY2017Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
5000
CY2016Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
8000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3600000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4966000
CY2017Q4 us-gaap Deferred Tax Assets State Taxes
DeferredTaxAssetsStateTaxes
6000
CY2016Q4 us-gaap Deferred Tax Assets State Taxes
DeferredTaxAssetsStateTaxes
9000
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
2640000
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
2379000
CY2017Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
495000
CY2016Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
940000
CY2017Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
165000
CY2016Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
201000
CY2016Q4 us-gaap Deferred Tax Assets Other Comprehensive Loss
DeferredTaxAssetsOtherComprehensiveLoss
252000
CY2017Q4 us-gaap Deferred Tax Assets Unrealized Currency Losses
DeferredTaxAssetsUnrealizedCurrencyLosses
84000
CY2016Q4 us-gaap Deferred Tax Assets Unrealized Currency Losses
DeferredTaxAssetsUnrealizedCurrencyLosses
136000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
33451000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
43687000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
41555000
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
54742000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
40866000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
54310000
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
689000
CY2016Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
432000
CY2017Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill
608000
CY2016Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill
876000
CY2017Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
185000
CY2016Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
354000
CY2017Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
793000
CY2016Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1230000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
147000000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
87000000
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
568000
CY2017 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
0
CY2017 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
0
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
568000
CY2017 biol Tax Cuts And Jobs Act Of2017 Change In Tax Rate Net Deferred Tax Assets Before Valuation Allowance Income Tax Expense Benefit
TaxCutsAndJobsActOf2017ChangeInTaxRateNetDeferredTaxAssetsBeforeValuationAllowanceIncomeTaxExpenseBenefit
-21700000
CY2017 biol Tax Cuts And Jobs Act Of2017 Change In Tax Rate Deferred Tax Liability Income Tax Expense Benefit
TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxExpenseBenefit
300000
CY2017 biol Tax Cuts And Jobs Act Of2017 Change In Rate Limitation On Utilization Of Net Operating Loss To Taxable Income Percentage
TaxCutsAndJobsActOf2017ChangeInRateLimitationOnUtilizationOfNetOperatingLossToTaxableIncomePercentage
0.80
CY2017Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
500000
CY2017Q4 biol Tax Cuts And Jobs Act Of2017 Change In Rate Deferred Tax Liability
TaxCutsAndJobsActOf2017ChangeInRateDeferredTaxLiability
100000
CY2017 biol Tax Cuts And Jobs Act Of2017 Change In Rate Recognized Deferred Tax Benefit
TaxCutsAndJobsActOf2017ChangeInRateRecognizedDeferredTaxBenefit
400000
CY2017Q4 us-gaap Undistributed Earnings Of Foreign Subsidiaries
UndistributedEarningsOfForeignSubsidiaries
600000
CY2017Q4 biol Lease Facility Area
LeaseFacilityArea
57000
CY2015Q1 biol Period For Extended Lease
PeriodForExtendedLease
2020-04-30
CY2015Q1 biol Provisions For Tenant Improvement Allowance Maximum
ProvisionsForTenantImprovementAllowanceMaximum
398000
CY2015Q1 biol Capital Lease Agreement Lease Term
CapitalLeaseAgreementLeaseTerm
P30M
CY2017 us-gaap Fair Value Inputs Discount Rate
FairValueInputsDiscountRate
0.016
CY2017Q4 biol Capital Leases Prepayments
CapitalLeasesPrepayments
14000000
CY2017Q4 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
0
CY2017Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
0
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
814000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
744000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
283000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
12000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1853000
CY2017 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1000000
CY2016 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1000000
CY2015 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1000000
CY2017Q4 us-gaap Unrecorded Unconditional Purchase Obligation Balance Sheet Amount
UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
10300000
CY2017 biol Dividend Declared
DividendDeclared
0
CY2016 biol Dividend Declared
DividendDeclared
0
CY2015 biol Dividend Declared
DividendDeclared
0
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
52000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.69
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.03
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.54
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1286000
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1728000
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2268000
CY2016Q2 biol Number Of Vice Presidents
NumberOfVicePresidents
2
CY2017Q2 biol Number Of Vice Presidents
NumberOfVicePresidents
1
CY2017Q1 biol Number Of Senior Vice President And Chief Financial Officer
NumberOfSeniorVicePresidentAndChiefFinancialOfficer
1
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3727000

Files In Submission

Name View Source Status
0001564590-18-005648-index-headers.html Edgar Link pending
0001564590-18-005648-index.html Edgar Link pending
0001564590-18-005648.txt Edgar Link pending
0001564590-18-005648-xbrl.zip Edgar Link pending
biol-10k_20171231.htm Edgar Link pending
biol-20171231.xml Edgar Link completed
biol-20171231.xsd Edgar Link pending
biol-20171231_cal.xml Edgar Link unprocessable
biol-20171231_def.xml Edgar Link unprocessable
biol-20171231_lab.xml Edgar Link unprocessable
biol-20171231_pre.xml Edgar Link unprocessable
biol-ex1026_499.htm Edgar Link pending
biol-ex1027_552.htm Edgar Link pending
biol-ex1028_553.htm Edgar Link pending
biol-ex1029_554.htm Edgar Link pending
biol-ex211_7.htm Edgar Link pending
biol-ex231_9.htm Edgar Link pending
biol-ex311_13.htm Edgar Link pending
biol-ex312_131.htm Edgar Link pending
biol-ex321_11.htm Edgar Link pending
biol-ex322_132.htm Edgar Link pending
biol-ex44_500.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending